Norepinephrine Bitartrate is a defined ionic salt form offering distinct advantages in pharmaceutical processing and performance over the free acid or base. The counter-ion in Norepinephrine Bitartrate has been selected based on toxicological acceptability at daily intake levels achievable from the proposed dosage regimen, and compatibility with the drug product excipient matrix. Solid-state characterisation of Norepinephrine Bitartrate includes polymorph screening, stability under accelerated conditions, and determination of hygroscopic behaviour that may affect powder processing, fill weight uniformity, and long-term chemical stability in the drug product.
Cleaning validation acceptance criteria for Norepinephrine Bitartrate in shared pharmaceutical equipment are determined using the health-based MACO formula: MACO (mg/batch) = PDE(mg/day) × MBS(g) ÷ TDD(g/day), where MBS is the minimum batch size of the next product and TDD its maximum daily therapeutic dose.
